Eli Lilly Initiates Phase 3 Clinical Trial of Oral GLP-1R Agonist Orforglipron (LY3502970) in China for Obesity and Overweight Patients

On August 11, the official website of the Chinese Drug Clinical Trial Registration and Information Disclosure Platform showed,Eli LillyEli Lilly and Company (LLY.US) has launched a global, multi-center (including China) Phase 3 clinical trial (ATTAIN-1 study) to evaluate the efficacy and safety of LY3502970 compared to placebo in participants who are obese or overweight with weight-related comorbidities. Public data indicates that LY3502970 (orforglipron) is an orally administered, once-daily small molecule GLP-1 receptor (GLP-1R) agonist. Results from a Phase 2 clinical trial published by Eli Lilly in June this year showed that adults who are obese or overweight experienced an average weight loss of 14.7% after 36 weeks of treatment with orforglipron.

According to the official website of the Chinese Drug Clinical Trial Registration and Information Disclosure Platform, this Phase 3, randomized, double-blind study (ATTAIN-1) initiated by Eli Lilly aims to evaluate the efficacy and safety of once-daily oral orforglipron compared to placebo in adult subjects who are obese or overweight with weight-related comorbidities. The primary objective of this study is to demonstrate the superiority of 6mg, 12mg, and/or 36mg once-daily orforglipron capsules over placebo in weight management. The study plans to enroll 3,000 participants internationally, including 280 participants in China.

It is worth mentioning that, in addition to orforglipron, which has just entered clinical trials, other weight-loss drugs from Eli Lilly, such as the GCGR/GIPR/GLP-1R triple agonist LY3437943 and the GIP/GLP-1 receptor dual agonist tirzepatide, are also currently undergoing clinical research in China targeting overweight or obese subjects.

Editorial Responsibility: Guo Mingyu